WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012112511) CHOLESTEROL ABSORPTION INHIBITOR (AZETIDINONE) AND OMEGA 3 FATTY ACIDS (EPA, DHA, DPA) FOR THE REDUCTION OF CHOLESTEROL AND FOR THE REDUCTION OF CARDIOVASCULAR EVENTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/112511    International Application No.:    PCT/US2012/025003
Publication Date: 23.08.2012 International Filing Date: 14.02.2012
IPC:
A61K 31/202 (2006.01), A61K 45/06 (2006.01), A61P 9/00 (2006.01), A61K 31/397 (2006.01)
Applicants: PIVOTAL THERAPEUTICS, INC. [CA/CA]; 81 Zenway Boulevard Unit 10 Woodbridge, Ontario L4H 0S5 (CA) (For All Designated States Except US).
JACKOWSKI, George [CA/CA]; (CA) (For US Only).
MACSWEENEY, Rachelle [US/CA]; (CA) (For US Only).
SHAIKH, Nisar [CA/CA]; (CA) (For US Only).
YANTHA, Jason [CA/CA]; (CA) (For US Only).
SCHINI-KERTH, Valerie [FR/FR]; (FR) (For US Only)
Inventors: JACKOWSKI, George; (CA).
MACSWEENEY, Rachelle; (CA).
SHAIKH, Nisar; (CA).
YANTHA, Jason; (CA).
SCHINI-KERTH, Valerie; (FR)
Agent: JOHNSON, Lance; Roylance, Abrams, Berdo & Goodman, L.L.P. 1300 19th Street, N.W. Suite 600 Washington, DC 20036 (US)
Priority Data:
61/457,268 16.02.2011 US
Title (EN) CHOLESTEROL ABSORPTION INHIBITOR (AZETIDINONE) AND OMEGA 3 FATTY ACIDS (EPA, DHA, DPA) FOR THE REDUCTION OF CHOLESTEROL AND FOR THE REDUCTION OF CARDIOVASCULAR EVENTS
(FR) INHIBITEUR DE L'ABSORPTION DU CHOLESTÉROL (AZÉTIDINONE) ET ACIDES GRAS OMÉGA 3 (EPA, DHA, DPA) POUR LA RÉDUCTION DU CHOLESTÉROL ET POUR LA RÉDUCTION DES ÉVÉNEMENTS CARDIOVASCULAIRES
Abstract: front page image
(EN)A composition and a method of treatment utilizing a combination of lipid lowering cholesterol absorption inhibitors, e.g. azetidinones, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DP A) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught. EPA + DHA are about 80% of the total formulation and about 89% of the total omega 3 fatty acid content of the composition. The formulation may further contain specific amounts of arachidonic acid (AA) and of omega-3 fatty acids having 18 carbon atoms, including one or more of stearidonic acid (SDA) and alpha-linolenic acid (ALA). The application further teaches methods of administering such combinations, and is directed towards unit dosages of such combinations for the reduction of risk factors for cardiovascular disease.
(FR)La présente invention concerne une composition et un procédé de traitement utilisant une combinaison d'inhibiteurs de l'absorption du cholestérol hypolipémiants, par exemple, des azétidinones, avec des mélanges d'une formulation d'acides gras oméga 3 contenant environ 90 % en poids ou plus d'acides gras oméga 3 y compris une combinaison d'acide eicosapentaénoïque (EPA), d'acide docosapentaénoïque (DPA) et d'acide docosahexaénoïque (DHA) en un rapport en poids d'EPA/DHA de 5,7 à 6,3, la somme de l'EPA, du DHA et du DPA représentant environ 82 % en poids de la formulation totale et environ 92 % de la teneur en acide gras oméga 3 totale de la composition. L'EPA + le DHA constituent environ 80 % de la formulation totale et environ 89 % de la teneur en acide gras oméga 3 de la composition. La formulation peut en outre contenir des quantités spécifiques d'acide arachidonique (AA) et d'acides gras oméga 3 ayant 18 atomes de carbone, y compris un ou plusieurs de l'acide stéaridonique (SDA) et de l'acide alpha-linolénique (ALA). La présente invention enseigne en outre des procédés d'administration de ces combinaisons, et concerne des unités posologiques de ces combinaisons pour la réduction des facteurs de risque de maladies cardiovasculaires.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)